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A relatively short peptide can be used as an immuno­
gen to elicit antibodies that are capable of reacting with 
full-length proteins containing the peptide's amino acid 
sequence. Such peptides are frequently represented in 
the primary sequence of a protein. The antibodies elic­
ited by these peptides are directed against a specific 
region of the protein chosen in advance by the investi­
gator and so have a predetermined specificity. In basic 
research, such antibodies are useful in identifying the 
gene product of an open reading frame, purifying en­
zymatically active proteins by immunoaffinity tech­
niques, and investigating protein folding domains and 
immunogenic structure and function. In medicine, since 
some peptides are capable of eliciting antisera that can 
bind to and neutralize virus, the antibodies may be re­
agents for passive vaccination, antitoxin therapy, and 
targeted immunotherapy of neoplasia. The peptides 
themselves may serve as the basis for safe, chemically 
defined vaccines. 
The observation that a short oligopeptide corresponding to 
virtually any surface-accessible region of a protein can elicit 
antibodies that react with the full-length protein has led to the 
development of a powerful new technology with applications in 
both basic research and medicine (reviewed in [1-3]). In part, 
the utility of this approach lies in the fact that essentially all 
one needs to produce antibodies that react with a given protein 
is its amino acid sequence, thus allowing one to circumvent 
problems often associated with proteins synthesized in small 
amounts, proteins that are difficult to isolate or purify, proteins 
associated with known pathogens, or proteins whose existence 
is merely inferred from a nucleotide sequence. The general 
approach and the immunogenicity and antigenicity of synthetic 
peptides have been recently reviewed [1-3]. Here we will briefly 
review the uses of this approach in basic research and then 
illustrate some of its possible practical applications in medicine 
with a review of work on the hepatitis B virus. 
APPLICATIONS IN MOLECULAR BIOLOGY 
Many of the uses of the protein-reactive peptide antibodies 
in basic research are reflected in two facets of the approach. 
First, as mentioned earlier, if one has the amino acid sequence 
of a protein, then one can use a synthetic peptide immunogen 
to elicit antibodies to that protein. This is particularly impor­
tant, since presently most amino acid sequences are generated 
by translation of nucleotide sequences and occasionally all one 
knows about a putative gene product is its deduced amino acid 
sequence. The protein-reactive peptide antibodies are excellent 
reagents for establishing the identity between a protein se-
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quence and the protein itself. Indeed, positive, coincident, 
specific reactivity with antibodies elicited by two or more 
different peptides from an amino acid sequence may be stronger 
evidence that a particular protein is encoded by a given gene 
than a series of genetic experiments. The antibodies can also 
be used to determine details of the cellular location and expres­
sion of the protein. The following example illustrates such uses. 
Other examples and uses may be found in the recent reviews 
[1-3]. 
To survey brain-specific protein expression in the rat, Milner 
and Sutcliffe [4] isolated and characterized a cDNA library of 
brain-specific messenger RNA molecules-the thought being 
that since all proteins of the brain are synthesized using specific 
mRNA transcripts, each brain-specific protein must have a 
corresponding brain-specific messenger RNA. What was 
needed, however, was a way to link the individual cDNA clones 
to their encoded proteins. To do this, Sutcliffe et al [5] used 
the synthetic peptide immunogen approach. First, the nucleo­
tide sequences of four of the cD N A clones were determined and 
the open reading frames were translated into amino acid se­
quence. Then using the deduced protein sequence as a blue­
print, short oligo pep tides were chosen and chemically synthe­
sized. The oligopeptides were coupled to a carrier protein and 
used to immunize rabbits. The resulting antisera should consist 
of specific reagents for identifying the protein product of the 
corresponding open reading frame. To detect the protein prod­
uct of one of the cDNA clones, pIA 75, two anti-peptide sera 
were used to probe protein extracts of a [8"S] methionine-labeled 
pheochromocytoma cell line (PCI2) that produces an mRNA 
species that hybridizes to the pIA 75 eDNA clone. Both anti­
peptide sera specifically detected a protein species of about 
28,000 daltons in these immunoprecipitation studies, thereby 
indicating that the protein product of the plA75 mRNA is a 
28,000 dalton protein. 
To determine the cellular and tissue localization of the pIA 75 
protein, thin, fixed sections of rat brain were reacted with the 
anti-peptide sera, the sections washed, and the antibody -anti ­
gen complexes visualized with horseradish peroxidase-coupled 
anti-rabbit immunoglobulin. The anti-peptide sera reacted spe­
cifically with the cell bodies of certain neurons located through­
out the brain, including many large neurons such as the cortical 
pyramidal cells, thus suggesting that the 28,000 dalton protein 
product of the pIA 75 mRNA is specifically expressed in a set 
of roughly homologous neurons. Furthermore, the reactivity 
had a granular appearance and seemed to be cytoplasmic, with 
the granules often concentrated in the dendritic pole of the cell 
as well as being frequently observed in the dendrites them­
selves. These observations suggest that the plA75 protein could 
be involved in the synthesis or directional transport of proteins 
destined for dendrites or could be a component of a cytoplasmic 
organelle such as mitochondria. 
So far we have seen how anti-peptide sera can identify the 
protein product of a gene and determine its cellular location, 
but how can one then determine the protein's biologic or 
enzymatic activity? If the protein has a suspected activity, then 
the antisera could be assayed for the ability to inhibit that 
activity. That is, if the anti-peptide serum can perturb an 
assayable protein function, then a protein containing the pep­
tide sequence must be capable of performing that function. For 
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example, antisera to peptides corresponding to portions of the 
polyoma virus middle-T protein [6] or the feline sarcoma virus 
fes gene product [7] inhibit protein kinase activity in vitro. 
Thus each protein must have protein kinase activity. If a 
function is not known, the anti-peptide antibodies can be used 
to purify the intact, native protein for biochemical studies. For 
example, the middle-T antigen of polyoma virus has been 
purified by immunoaffinity chromatography using anti-peptide 
antibodies as the immunosorbent [8]. A key advantage of the 
anti-peptide antibodies in this procedure is that the protein 
can be recovered in an enzymatically active form by gently 
eluting it from the immunoaffinity column by competition with 
an excess of peptide. Alternatively, the anti-peptide sera could 
be used as specific probes for the protein during various steps 
in a classical enzyme isolation procedure. 
The second key facet of the synthetic peptide immunogen 
approach is that the peptide-elicited antibodies react with a 
small region of the protein that is chosen in advance by the 
investigator. As such, the anti-peptide sera are reagents for 
following the fate of particular portions of the protein through 
protein-processing pathways. For example, by using a peptide­
elicited serum specific for the carboxyl-terminal 15 residues of 
the predicted protein of the envelope gene of Moloney murine 
leukemia virus, we were able to t.rack this region from the 
precursor polyp rote in to an intermediate product and then 
show that the mature protein was generated by removal of a 
carboxyl-terminal peptide from the intermediate [9]. Such pre­
determined specificity of binding can also be exploited in the 
analysis of DNA or RNA rearrangements that alter protein 
sequence, such as occurs during immunoglobulin production 
[10,11] or adenovirus transcription [12-14]. For example, the 
E1A transcription unit of adenovirus encodes three mRNAs 
that have overlapping nucleotide sequences and encode proteins 
that share amino acid sequences [12-14]. Given the common 
sequences, it would be very difficult to produce antibodies 
specific for only one of the proteins by conventional means, 
but with the synthetic peptide immunogen approach, the anti­
bodies can be targeted to the sequences that differ. In this 
example, Feldman and Nevins [14] used a 13-residue peptide 
that had a sequence unique to the product of the 13S E1A 
mRNA to elicit antisera specific to that protein. The antisera 
were subsequently used as specific probes to study the function 
and cellular localization of this protein. In sum, the peptide 
immunogen approach provides a powerful set of reagents of 
predetermined specificity with which to investigate protein 
expression, processing, localization, and activity. 
APPLICATIONS IN MEDICINE 
The synthetic peptide immunogen approach holds promise 
for the development of reagents for the detection, treatment 
and prevention of disease. Indeed, given the exquisite predeter­
mined specificity of the peptide-elicited protein-reactive anti­
bodies, it may be possible to design and produce antibody 
reagents with precisely defined reactivities. In the detection of 
disease, the peptide-elicited antibodies specific for a protein of 
a pathogenic agent could form the basis of an immunoassay to 
detect or identify the pathogen. Here, the antibody specificity 
might be exploited to distinguish between closely related path­
ogens such as different serotypes of a virus (discussed below). 
In the treatment of disease, the protein-reactive antibodies 
might be useful in passive immunization protocols, antitoxin 
therapies, or targeted immunotherapy of neoplasia. In the 
prevention of disease, the peptides might serve as the basis of 
safe, chemically defined synthetic vaccines. Although none of 
these reagents has yet been sufficiently refined for use in the 
hospital , a brief review of our studies with hepatitis B virus will 
be helpful to illustrate the potential for clinical application. 
Hepatitis B virus (serum hepatitis) infection leads to a ful­
minant hepatic disease with parenchymal cell degeneration, 
necrosis, and inflammation. The natural immune response to 
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hepatitis B virus infection involves the production of neutral­
izing antibodies that are primarily directed against the hepatitis 
B virus surface antigen (HBsAg) [15-18]. This protein also 
carries the three serotypic markers that define the four possible 
serotypes of the hepatitis B virus: adw, ayw, adr, and ayr [15-
18]. Hence we have chosen to study the immunology of this 
virus by analyzing the precise chemical nature of synthetic 
oligopeptides corresponding to portions of the HBsAg sequence 
that can mimic the serotypic markers-the thought being that 
if the serotypic markers are a direct reflection of the specificity 
of neutralizing antibodies, then we should be able to learn how 
to use synthetic pep tides to elicit neutralizing antibodies. 
Since the serotypic markers map to the HBsAg, serotype 
variation must be caused by a variation in the immunogenic 
and antigenic structure of the HBsAg, which, in turn, should 
be reflected in variations in the amino acid sequence of HBsAg. 
Therefore, we began our study by comparing the amino acid 
sequences of the HBsAg from three strains of hepatitis B virus 
in order to get an idea of which portions of the polypeptide 
might be responsible for the serotypic variation [19-23]. 
Thirteen of the 19 positions that varied between the three 
strains were scattered throughout the 226-residue primary se­
quence, but 6 changes were clustered in a 21-residue region, 
amino acids 114-134, thereby suggesting that this region might 
be involved in serotypic variation. We have synthesized and 
analyzed four peptides from this region [22-24]: peptides 49 
and 49a, which correspond to residues 110-137 and 125-137, 
respectively, of the HBsAg amino acid sequence as deduced 
from the nucleotide sequence of a virus displaying the ayw 
serotype, and peptides 72 and 72a, which correspond to residues 
110-137 and 125-137, respectively, of the amino acid sequence 
of an HBsAg of adw serotype (Table I; also [23,24]). The 
peptides were coupled to a carrier protein and used to immunize 
rabbits. The resulting antisera were assayed for the ability to 
react with the HBsAg of serotype adw or ayw in a solid-phase 
enzyme-linked immunosorbent assay (Table II). The antibodies 
TABLE I. Sequence of hepatitis B surface antigen peptides 
Peptide Residues Serotype" Sequence· number 
49a 125-137 y Met-Thr-Thr-Ala-Gln-Gly-Thr-
Ser-Met-IY!:-Pro-Ser-Cys 
49 110-137 y Phe-Pro-Gly-Ser-Ser-Thr-Thr-
Ser-Thr-Gly-Pro-Cys-Arg -Thr 
Cys- Met-Thr-Thr-Ala-Gln-Gly-
Thr-Ser-Met-fu-Pro-Ser-Cys 
72a 125-137 d Thr-Thr-Pro-Ala-Gln-Gly-Asn-
Ser- Met-Phe-Pro-Ser-Cys 
72 110-137 d Ile-Pro-G Iv-Ser-Thr-Thr-Thr -Ser-Thr�Gly-Pro-Cys-�-Thr 
Cys-Thr-Thr-Pro-Ala-Gln-Gly-
Asn-Ser-Met-Phe-Pro-Ser-Cys 
a Serotype of HBsAg containing the peptide sequence. 
b Underlined residues vary between the HBsAg/adw and HBsAg/ 
ayw sequences. 
T ABLE II. Serotype specificity of peptide-elicited antisera 
Antibody titer· against 
Peptide Residues Expected HBsAg of serotype number serotypell 
adw ayw 
49a 125-137 y 0 1280-2560 
49 110-137 y 80-160 1280-2560 
72a 125-137 d 1280-2560 0 
72 110-137 d 640-1280 40-80 
a Serotype of HBsAg containing the peptide sequence. 
h Antibody titers were determined in a solid-phase enzyme-linked 
immunosorbent assay and are expressed as the reciprocal of the range 
of dilution that bound 50% of 5 pmol of antigen. A 0 indicates no 
activity in undiluted serum. 
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elicited by the peptides corresponding to residues 125-137 (49a, 
72a) displayed strict serotype specificity; the anti-peptide 49a 
antibodies reacted only with the HBsAg/ayw and the anti­
peptide 72a antibodies reacted only with the HBsAg/adw. This 
suggests that the region between positions 125-137 plays an 
important role in the expression of the two mutually exclusive 
serotypes d and y and that at least a portion of this serotypic 
difference is reflected in the four amino acid differences in this 
region. The antibodies elicited by the longer peptides (42, 72) 
bound to both HBsAg/adw and HBsAg/ayw, but showed a clear 
preference for the corresponding serotype. For example, the 
anti-peptide 49 antibodies displayed a 10- to 20-fold higher 
titer against HBsAg/ayw than HBsAg/adw. The slight cross­
reactivity suggests that residues 110-137 carry an a determi­
nant (the determinant or set of determinants shared in common 
by all hepatitis B virus strains) in addition to the y or d 
determinant. Indeed, as suggested, peptide 49 can be immuno­
precipitated by antibodies monospecific for the a determi­
nant(s). 
From an analysis of a set of peptides corresponding to resi­
dues 110-137 that varies by one or a few amino acids we should 
be able to precisely define the chemical nature of the d/y 
serotype determinant. Obviously, such studies will provide im­
portant information on the virology and immunology of this 
virus, but of what possible medical significance are these pep­
tides or anti-peptide sera? The protein-reactive antibodies 
could form the basis of an immunoassay for the presence of 
HBsAg or hepatitis B virus in serum samples, i.e., a diagnostic 
test for serum hepatitis. In addition, the strict serotypic speci­
ficity of the antibodies elicited by peptides 42a and 72a might 
be exploited to determine the d/y serotype of the virus. For 
example, one possible solid-phase immunoassay might involve 
first coating the wells of a polystyrene microtiter plate with 
antibodies elicited by one of the HBsAg peptides. The serum 
samples to be tested would then be added. The immobilized 
antibodies should bind any HBsAg present in the samples. 
After washing to remove unbound proteins, the bound HBsAg 
could be visualized by first adding a solution containing an 
enzyme-linked anti-HBsAg antibody (e.g., horseradish peroxi­
dase-coupled goat anti-HBsAg), washing to remove unbound 
antibody, and then adding a chromogenic substrate for the 
enzyme (e.g., H202 and O-phenylenediamine for horseradish 
peroxidase). The HBsAg serotype could be determined similarly 
by using one of the serotype-specific antibodies as the immo­
bilized antibody and a broadly HBsAg-specific antibody for the 
enzyme-linked antibody, or vice versa. Three possible advan­
tages of anti-peptide antibodies in such assays are the ease of 
production of serotype-specific antibodies (currently a labori­
ous adsorption procedure), the availability of a stable, easy-to­
manufacture positive control (the peptides), and the absence of 
a pathogenic agent in the production of the antisera. 
If the d/y serotype variation in the immune response to 
hepatitis B virus infection (which is defined on the basis of in 
vitro binding assays) is a consequence of a variation in the 
reactivities of neutralizing antibodies, then we have identified 
a region of the hepatitis B surface antigen that interacts with 
the biologically important neutralizing antibodies. If so, then 
we have identified synthetic peptide reagents that can immu­
nologically mimic an immunogenic site of the virus that elicits 
neutralizing antibodies. One might expect that these synthetic 
peptides could form the basis of a chemically defined vaccine 
against hepatitis B virus. Indeed, in one preliminary experi­
ment, the immunization of chimpanzees with peptide 49 pro­
vided at least partial immunologic protection from challenge 
with the homologous hepatitis B virus [23]. In addition, since 
there appear to be only two possible serotypes at the d/y locus, 
a vaccine that might provide protection against all the known 
serotypes of hepatitis B virus might be made by combining a 
synthetic peptide immunogen that elicits an anti-y response 
with one that elicits an anti-d response. Once again, some 
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advantages of the synthetic peptide immunogen approach are 
that one does not have to grow or handle large quantities of 
the pathogenic agent, which is, of course, required for produc­
tion of the conventional vaccine, the excellent stability of 
peptides at room temperature, and the ability to precisely 
chemically define the immunogen and thereby produce a vac­
cine free of any biological contamination. 
DIRECTION OF FUTURE STUDIES 
In basic research, the uses of peptides and the elicited anti­
bodies have centered on identifying, localizing, and character­
izing proteins and their expression. Questions amenable to the 
synthetic peptide immunogen approach that are yet to be fully 
explored include the precise chemical nature of a "tolerated" 
epitope, the fluidity of proteins in solution, the ability of 
antibodies to induce conformational changes in proteins and 
peptides, and the precise chemical nature of antigenic or im­
munogenic variation. In medicine, much effort needs to be 
devoted to developing and refining laboratory procedures to the 
degree of sophistication required for widespread clinical appli­
cation. For example, a key question that must be addressed 
before synthetic peptide immunogens can be used as vaccines 
involves the use and choice of adjuvants or carriers, since the 
ones used in the laboratory are in general too harsh for use in 
humans and animals_ Nonetheless, the synthetic peptide im­
munogen approach should generate much new basic informa­
tion on protein structure, function, and immunochemistry, as 
well as generate novel, well-defined reagents for combatting 
disease. 
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